ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

Post-LOE

isosorbide dinitrate and hydralazine hydrochloride

Pharmazone

ANDAORALTABLET

Approved

Jan 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE (isosorbide dinitrate and hydralazine hydrochloride) by Pharmazone is 12. Approved for heart failure, to prolong time to hospitalization for heart failure, to improve patient-reported functional status. First approved in 2024.

Drug data last refreshed 3h ago

Mechanism of Action

12.1 Mechanism of Action The mechanism of action underlying the beneficial effects of isosorbide dinitrate and hydralazine hydrochloride tablets in the treatment of heart failure has not been established. Isosorbide dinitrate is a vasodilator affecting both arteries and veins. Its dilator…

Worked on ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE at Pharmazone? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

Mechanism of Action

Indications (3)